NP49124 Hepatitis C Medicines
Estimated value
—
Awarded value
—
Suppliers
7
Lots
3
Published
21 Mar 2024
Description
Supply of Hepatitis C Medicines to NHS Scotland.
Scope
- Reference
- ocds-h6vhtk-041e33
- Commercial tool
- Standalone contract
- Contract dates
This framework includes the option to extend for any number of periods, up to a maximum overall period of forty-eight (48) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- Scotland
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Treatment duration | 2.5 | quality | — |
| Genotype testing | 2.5 | quality | — |
| — | 95 | price | — |
| — | — | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 3 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Lots · 3 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | Hepatitis C - Treatment Cost per Medicine | £35.8m | cancelled |
| 2 | Hepatitis C Medicines - Price submitted based on Volume (unscored) | — | cancelled |
| 3 | Hepatitis C Medicines - Price submitted based on Volume (unscored) | — | cancelled |
Award 1· 3 suppliers
Awarded —
Award 2· 2 suppliers
Awarded —
Award 3· 2 suppliers
Awarded —
Total lots
3
Awarded
3
Estimated total
£35.8m
Awarded total
—
Hepatitis C - Treatment Cost per Medicine
Start
—
End
—
Estimated
£35.8m
CPV
Hepatitis C Medicines - Price submitted based on Volume (unscored)
Start
—
End
—
Estimated
—
CPV
Hepatitis C Medicines - Price submitted based on Volume (unscored)
Start
—
End
—
Estimated
—
CPV
Other contracts from NHS Scotland
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to AbbVie Ltd· 10
Cross-buyer view of this supplier's public-sector wins.